Cargando…

Tumour treating fields in a combinational therapeutic approach

The standard of care for patients with newly diagnosed Glioblastoma multiforme (GBM) has remained unchanged since 2005, with patients undergoing maximal surgical resection, followed by radiotherapy plus concomitant and maintenance Temozolomide. More recently, Tumour treating fields (TTFields) therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Branter, Joshua, Basu, Surajit, Smith, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290966/
https://www.ncbi.nlm.nih.gov/pubmed/30564303
http://dx.doi.org/10.18632/oncotarget.26344
_version_ 1783380179976978432
author Branter, Joshua
Basu, Surajit
Smith, Stuart
author_facet Branter, Joshua
Basu, Surajit
Smith, Stuart
author_sort Branter, Joshua
collection PubMed
description The standard of care for patients with newly diagnosed Glioblastoma multiforme (GBM) has remained unchanged since 2005, with patients undergoing maximal surgical resection, followed by radiotherapy plus concomitant and maintenance Temozolomide. More recently, Tumour treating fields (TTFields) therapy has become FDA approved for adult recurrent and adult newly-diagnosed GBM following the EF-11 and EF-14 trials, respectively. TTFields is a non-invasive anticancer treatment which utilizes medium frequency alternating electric fields to target actively dividing cancerous cells. TTFields selectively targets cells within mitosis through interacting with key mitotic proteins to cause mitotic arrest and cell death. TTFields therapy presents itself as a candidate for the combinational therapy route due to the lack of overlapping toxicities associated with electric fields. Here we review current literature pertaining to TTFields in combination with alkylating agents, radiation, anti-angiogenics, mitotic inhibitors, immunotherapies, and also with novel agents. This review highlights the observed synergistic and additive effects of combining TTFields with various other therapies, as well highlighting the strategies relating to combinations with electric fields.
format Online
Article
Text
id pubmed-6290966
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-62909662018-12-18 Tumour treating fields in a combinational therapeutic approach Branter, Joshua Basu, Surajit Smith, Stuart Oncotarget Review The standard of care for patients with newly diagnosed Glioblastoma multiforme (GBM) has remained unchanged since 2005, with patients undergoing maximal surgical resection, followed by radiotherapy plus concomitant and maintenance Temozolomide. More recently, Tumour treating fields (TTFields) therapy has become FDA approved for adult recurrent and adult newly-diagnosed GBM following the EF-11 and EF-14 trials, respectively. TTFields is a non-invasive anticancer treatment which utilizes medium frequency alternating electric fields to target actively dividing cancerous cells. TTFields selectively targets cells within mitosis through interacting with key mitotic proteins to cause mitotic arrest and cell death. TTFields therapy presents itself as a candidate for the combinational therapy route due to the lack of overlapping toxicities associated with electric fields. Here we review current literature pertaining to TTFields in combination with alkylating agents, radiation, anti-angiogenics, mitotic inhibitors, immunotherapies, and also with novel agents. This review highlights the observed synergistic and additive effects of combining TTFields with various other therapies, as well highlighting the strategies relating to combinations with electric fields. Impact Journals LLC 2018-11-27 /pmc/articles/PMC6290966/ /pubmed/30564303 http://dx.doi.org/10.18632/oncotarget.26344 Text en Copyright: © 2018 Branter et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Branter, Joshua
Basu, Surajit
Smith, Stuart
Tumour treating fields in a combinational therapeutic approach
title Tumour treating fields in a combinational therapeutic approach
title_full Tumour treating fields in a combinational therapeutic approach
title_fullStr Tumour treating fields in a combinational therapeutic approach
title_full_unstemmed Tumour treating fields in a combinational therapeutic approach
title_short Tumour treating fields in a combinational therapeutic approach
title_sort tumour treating fields in a combinational therapeutic approach
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290966/
https://www.ncbi.nlm.nih.gov/pubmed/30564303
http://dx.doi.org/10.18632/oncotarget.26344
work_keys_str_mv AT branterjoshua tumourtreatingfieldsinacombinationaltherapeuticapproach
AT basusurajit tumourtreatingfieldsinacombinationaltherapeuticapproach
AT smithstuart tumourtreatingfieldsinacombinationaltherapeuticapproach